ARTICLE | Finance
Coda’s chemogenetic control
Coda to bring chemogenetically activated gene therapy to the clinic with $19M
September 14, 2018 9:51 PM UTC
Coda Biotherapeutics Inc. could have first-mover potential in the chemogenetics space, and with a newly raised $19 million series A round, the company will move its first program toward the clinic.
Seed investors MPM Capital and Versant Ventures led the round, which closed on Sept. 12. New investors Astellas Venture Management and Novartis AG (NYSE:NVS; SIX:NOVN) also participated. ...
BCIQ Company Profiles